
# **Glycomic Determinants of Gut Microbial Dysbiosis and Translocation During Suppressed HIV Infection**


Leila B Giron<sup>1</sup>, Ceylan E Tanes<sup>2</sup>, Alitzel Anzurez<sup>1</sup>, Mohammad Darma<sup>1</sup>, Phillip A. Engen<sup>3</sup>, Lisa M Mattei<sup>2</sup>, Mariane H. Schleimann<sup>4</sup>, Kyle Bittinger<sup>2</sup>, Paul W. Denton<sup>4</sup>, Frederic Bushman<sup>5</sup>, Hiroaki Tateno<sup>6</sup>, Ali Keshavarzian<sup>3</sup>, Alan L. Landay<sup>3</sup>, Mohamed Abdel-Mohsen<sup>1</sup>.


The Wistar Institute, USA; <sup>2</sup>CHOP Microbiome Program, Children's Hospital of Philadelphia, USA; <sup>3</sup>Rush University Medical Center, USA; <sup>4</sup>Aarhus University Hospital and Department of Clinical Medicine, Denmark; <sup>5</sup>University of Pennsylvania, USA; <sup>6</sup>National Institute of Advanced Industrial Science and Technology (AIST), Japan.

### Introduction




2) Mucosal glycosylation may play a role in microbial composition shift during ART-suppressed HIV infection. Increasing levels of Bacteroides genus correlate with lower sialylated glycans and higher hypo-sialylated glycans (in particular, Gal-GalNAc, also known as T-antigen or TF-antigen). These correlations are compatible with what known that Bacteroides release sialidase.





- An emerging paradigm suggests that gut glycosylation is a key force in maintaining a homeostatic relationship between the gut and its microbiota. In the general population, changes in the gut glycome can alter the gut microbial composition, leading to microbial dysbiosis and gut inflammation.
- In HIV-infected individuals, microbial dysbiosis and translocation contribute to the vicious cycle between HIV and immune activation/ inflammation. This cycle likely contributes to the development of non-AIDS inflammatory-related illnesses and HIV persistence. However, how gut glycosylation machinery contributes to this cycle is yet to be characterized.
- Here we investigated the role of altered gut glycans in modulating the gut microbiome and mediating HIV-associated gut inflammation.

#### **Methods**




3) Mucosal sialic-acid catabolism and gut fucosylation associate with markers of microbial diversity and dysbiosis during ART-suppressed **HIV infection.** (A) Correlations with alpha diversity (decreased in HIV infection; the higher the better) and with **(B)** Bacteriodetes/Firmicutes (increased in HIV infection; the higher the worse)

Α	Р	r	Glycan	Lectin	Metric	Tissue Type
	0.013	0.55	Sialylated O glycans	ACG	Shannon	lleum
	0.016	0.53	LacNac, Sialic acid	rGal8N	Shannon	lleum
	0.001	-0.68	T Antigen, Mostly Hypo-Sialylated	rABA	Shannon	lleum
	0.005	-0.6	T Antigen, Mostly Hypo-Sialylated	DBA	Shannon	lleum
	0.032	0.48	α1,2 Fucose	TJAII	Richness	lleum

P r		Glycan	Lectin	Tissue Type
0.049	-0.45	Sialylated O glycans	ACG	lleum
0.003	0.64	T Antigen, Mostly Hypo-Sialylated	rABA	lleum
		0.049 -0.45	0.049 -0.45 Sialylated O glycans	0.049 -0.45 Sialylated O glycans ACG


#### **Results**

1) The gut glycome is compartmentalized between lleum, right colon, and **sigmoid colon.** A decrease in fucose, an increase of sialic acid, and an increase of mannose when going from the ileum to the colon. FDR<0.05. Permanova test on euclidean distances < 0.05



0.006	0.6	T Antigen, Mostly Hypo-Sialylated	DBA	lleum	
0.01	0.56	T Antigen, Mostly Hypo-Sialylated	HPA	lleum	7
0.009	-0.57	α1,2 Fucose	TJAII	lleum	

4) Mucosal sialic-acid catabolism and gut fucosylation associate with markers of inflammation during ART-suppressed HIV infection. (A) Levels of sialylated O-glycans in the illeum correlated with lower levels of sCD163. (B) Mucosalassociated  $\alpha$  1-2 fucose correlated with lower plasma levels of sCD163 in sigmoid colon.



5) Glycomic T antigen correlates with ileum-associated HIV DNA during ART**suppressed HIV infection. (A)** Total HIV DNA distribution between tissues. **(B)** Levels of hypo-sialylated glycans correlated with higher lleum-associated total HIV

## Conclusions

- Our pilot study provides the first proof-of-concept evidence that differential gut glycomic patterns (mainly sialylated and fucosylated glycans) support distinct microbiome compositions that predispose to microbial translocation, inflammation, and HIV persistence.
- Our data are consistent with previous general population reports which demonstrated that sialic acid catabolism drives microbial dysbiosis and intestinal inflammation and that gut fucosylation sustains host-commensal symbiosis and prevents gut inflammation.
- Exploiting gut glycosylation machinery may allow the design of strategies to manipulate it to prevent/delay the development of HIV-associated co-morbidities.

